Venous Thromboembolism – Landscape & Forecast – Disease Landscape & Forecast

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction. Pharmacological treatment of patients diagnosed with VTE consists mainly of anticoagulant therapy and, in some severe cases such as PE, thrombolytics. Patients at high risk of VTE receive primary prophylaxis with anticoagulants. These patients include hospitalized medically ill patients, patients undergoing orthopedic or non-orthopedic surgery, and cancer patients. In recent years, oral direct FXa inhibitors have become more widely used and have driven the growth of the VTE market. Therapies in the VTE pipeline include Anthos Therapeutics’ abemaciclib and Bristol Myers Squibb / Johnson & Johnson Innovative Medicine’s milvexian. Both are factor XI/XIa inhibitors and may prove safer than current therapies.

Questions answered

• What are the key treatment drivers and goals within VTE? How do current therapies perform on these goals?
• What do key opinion leaders think about Anthos Therapeutics’ abemaciclib and Bristol Myers Squibb / Johnson & Johnson Innovative Medicine’s milvexian?
• How will genericization affect the market?
• What are the key unmet needs in the treatment of VTE, and how likely are they to be met?

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading hematologists, internists, cardiologists, orthopedic surgeons, vascular surgeons, and oncologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Diagnosed and drug-treated VTE patients and patients eligible for VTE prophylaxis by country

Forecast: 10-year, annualized, drug-level sales and patient share of key VTE therapies through 2033, segmented by brands / generics

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Solution enhancements

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.